Risk factors for lenvatinib‐induced hypertension in patients with hepatocellular carcinoma: A retrospective study
Low K, high Alb and low ALBI were independent risk factors for LENiHTN. Systematic evaluation of HTN risk and early intervention for HTN prevention among high-risk patients can markedly enhance LEN therapy efficacy and use.
Authors
- Takahiro Μatsumoto (ORCID: https://orcid.org/0000-0003-2408-669X)
- Noritaka Wakui (ORCID: https://orcid.org/0000-0002-9957-8210)
- Sachiko Yanagino
- Yuki Hanai (ORCID: https://orcid.org/0000-0002-4606-7150)
- Yoshiki Arita
- Koji Higai (ORCID: https://orcid.org/0000-0003-3870-396X)
- Shusuke Uekusa (ORCID: https://orcid.org/0000-0003-0993-6019)
- Hidenari Nagai (ORCID: https://orcid.org/0000-0001-8802-4936)
- Misaki Nakashin
- Kazuhiro Matsuo
- Maho Nemoto
Institutions
- Toho University (JP)
- Toho University Ohashi Medical Center (JP)
- Toho University Omori Medical Center (JP)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1111/bcp.16337
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Eisai